Icatibant로 급성 악화를 치료한 제2형 유전성혈관부종 1예
Type 2 hereditary angioedema treated with acute exacerbation with icatibant: A case report
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-esterase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and long-term prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antagonist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diagnosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treatment could improve quality of life and reduce morbidity and mortality.
Abstract
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-esterase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and long-term prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antagonist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diagnosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treatment could improve quality of life and reduce morbidity and mortality.
참고문헌 (20)
- The Korean Academy of Asthma, "Allergy, and Clinical Immunology. Asthma and allergic diseases", pp.415~429 (2012), Yeomungak
- Davis AE 3rd, "The pathophysiology of hereditary angioedema", Clin Immunol, 114, pp.3~9 (2005)
- Longhurst H, "Hereditary angioedema", Lancet, 379, pp.474~481 (2012)
- Bork K, "Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency", J Allergy Clin Immunol, 130, pp.692~697 (2012)
- Maurer M, "The international WAO", EAACI guideline for the management of hereditary angioedema-the 2017 revision and update, 2018, pp.11, 5~
- Bork K, "Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency", Arch Intern Med, 163, pp.1229~1235 (2003)
- 심다운, "A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation", Allergy, Asthma & Immunology Research, 9(1), pp.96~98 (2017), 대한천식알레르기학회
- Jung JW, "Clinical features of hereditary angioedema in Korean patients : a nationwide multicenter study", Int Arch Allergy Immunol, 176, pp.272~279 (2018)
- Zotter Z, "The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency", Orphanet J Rare Dis, 9, pp.44~ (2014)
- Busse PJ, "Hereditary angioedema", N Engl J Med, 382, pp.1136~1148 (2020)
- Bork K, "Benefits and risks of danazol in hereditary angioedema : a long-term survey of 118 patients", Ann Allergy Asthma Immunol, 100, pp.153~161 (2008)
- Cicardi M, "Classification, diagnosis, and approach to treatment for angioedema : consensus report from the Hereditary Angioedema International Working Group", Allergy, 69, pp.602~616 (2014)
- 이서영, "설문조사를 통한 국내 유전성 혈관부종 진료 현황 및 국내 사례 문헌고찰", Allergy Asthma & Respiratory Disease, 2(4), pp.277~284 (2014), 대한 소아알레르기 호흡기학회
- Jonathan AB, "Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema", Int J Emerg Med, 5, pp.1~13 (2012)
- Betschel S, "The international", canadian hereditary angioedema guideline, 2019, pp.15, 7~16
- Bygum A, "Hereditary angio-oedema in Denmark : a nationwide survey", Br J Dermatol, 161, pp.153~158 (2009)
- Zanichelli A, "A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy", Orphanet J Rare Dis, 10, pp.11~ (2015)
- Lopez-Lera A Garrido S, "SERPING1 mutations in 59 families with hereditary angioedema", Mol Immunol, 49, pp.18~27 (2011)
- Pappalardo E, "Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema", J Allergy Clin Immunol, 106, pp.1147~1154 (2000)
- Lumry WR, "Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3", Int Arch Allergy Immunol, 168, pp.44~55 (2015)